Research Article
One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study
Table 2
Oral anticoagulant and antiplatelet agents and other cardiovascular medications in patients with AF and two subgroups of NVAF and VAF.
| Medication | All AF cohort | NVAF (91.5%) | VAF (8.5%) | value |
| Anticoagulant agents | | | | | DOACs, (%) | 970 (48.0) | 955 (51.6) | 15 (8.8) | <0.0001 | VKA, (%) | 649 (31.1) | 499 (27.0) | 150 (87.7) | <0.0001 | LMWH,(%) | 46 (2.3) | 46 (2.5) | 0 (0) | 0.07 | None, (%) | 355 (17.6) | 349 (18.9) | 6 (3.5) | <0.0001 | Antiplatelet agents | | | | | Single agent, (%) | 774 (38.3) | 726 (39.3) | 48 (28.0) | 0.01 | Dual agents, (%) | 126 (6.2) | 124 (6.7) | 2 (1.2) | 0.01 | Single or dual agents, (%) | 900 (44.6) | 850 (46.0) | 50 (29.2) | <0.0001 | Antiarrhythmic and rate control medications | | | | | Amiodarone | 387 (19.2) | 358 (19.4) | 29 (17.0) | 0.51 | Class I antiarrhythmic medications | 38 (1.9) | 36 (1.9) | 2 (1.2) | 0.72 | Beta blockers, (%) | 1619 (80.1) | 1474 (79.7) | 145 (84.8) | 0.13 | Digitalis, (%) | 319 (15.8) | 260 (14.1) | 59 (34.4) | <0.0001 | Nondihydropyridine CCB, (%) | 219 (10.8) | 210 (11.4) | 9 (5.3) | 0.02 | Other cardiovascular medications | | | | | RAS inhibitors,(%) | 781 (38.7) | 741 (40.1) | 40 (23.4) | <0.0001 | Diuretics, (%) | 792 (39.2) | 712 (38.5) | 80 (46.8) | 0.04 | Statins, (%) | 753 (37.3) | 715 (38.7) | 38 (22.2) | <0.0001 |
|
|
AF: atrial fibrillation; chronic kidney disease; CCB: calcium channel blocker; DOACs: direct oral anticoagulant agents, LMWH: low molecular weight heparin; LVH: left ventricular hypertrophy; NVAF: nonvalvular AF; VAF: valvular AF. RAAS: renin angiotensin system blockers; VKA: vitamin K antagonists. Difference between NVAF and VAF patients. Transthoracic echocardiography was done for 90% of patients. |